TG Therapeutics | TGTX - Sales Revenues

Stock Price
30.35
Daily Change
-0.55 -1.78%
Monthly
0.13%
Yearly
0.86%
Q1 Forecast
28.61

TG Therapeutics reported $192.57M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.62B 840M Dec/2025
Alaunos Therapeutics USD 2K 2K Mar/2025
Amgen USD 9.9B 340M Dec/2025
Ardelyx USD 110.33M 12.67M Sep/2025
Arrowhead Research USD 264.03M 7.56M Dec/2025
Bayer EUR 9.66B 1.08B Sep/2025
Biogen USD 2.28B 250M Dec/2025
Corcept Therapeutics USD 202.12M 5.48M Dec/2025
Curis USD 2.55M 460K Jun/2024
Gilead Sciences USD 7.93B 130M Dec/2025
Infinity Pharmaceuticals USD 583K 148K Jun/2023
J&J USD 24.6B 610M Dec/2025
Karyopharm Therapeutics USD 30.54M 8.24M Dec/2024
Novartis USD 13.91B 144M Sep/2025
Novavax USD 84.51M 330.97M Sep/2024
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
TG Therapeutics USD 192.57M 30.87M Dec/2025
Verastem USD 0 10M Sep/2024
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025